Biotech Values

[willyw]

CVS is going to be under considerable pressure to give. If they do not, they really call into question if they are there to negotiate lower prices or simply to act as another middleman expense to be borne. They could be open to several challenges from various groups.

In addition, most drug companies have had patience assistance programs where if you are turned down for a treatment the drug company can still in effect broker your treatment, for reduced cost. Gilead had these when the insurance companies wouldn't pay the high cost of Sovaldi and Harvoni.
Now.....rather remarkably, CVS seems to be unlisting Mavyret since the cost is too low. : )

From what I can tell CVS may be the lone standout and they may possibly "cave" as the date approaches.


http://www.natap.org/

"AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017

16 HCV abstracts to be presented including 12 data presentations on the safety and efficacy of MAVYRET

- MAVYRET is recommended in new AASLD guidelines as a first line treatment option for 8 weeks in treatment-naïve non-cirrhotic HCV patients across all genotypes (GT1-6)

NORTH CHICAGO, Ill., Oct. 11, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced that it will present new data evaluating MAVYRET™ (glecaprevir/pibrentasvir), its once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Sixteen AbbVie scientific abstracts have been accepted, including two oral presentations studying the use of MAVYRET in patients across genotypes (GT1-6) with compensated cirrhosis and treatment-naïve patients with genotype 3 (GT3) HCV. These populations have historically had limited treatment options. A third oral presentation evaluates adherence to treatment with MAVYRET in the clinical development program. The Liver Meeting® 2017 will take place in Washington, D.C., from October 20 - 24, 2017."